BMS-935177 NEW
| Price | $62 | $89 | Get Latest Price |
| Package | 1mg | 2mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-08 |
Product Details
| Product Name: BMS-935177 | CAS No.: 1231889-53-4 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2026/07/08 |
Product Introduction
Bioactivity
| Name | BMS-935177 |
| Description | BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM. |
| In vitro | In human Ramos B cells, BMS-935177 inhibits calcium flux with an IC50 of 27 nM. BMS-935177 inhibits CD69 surface expression in peripheral B cells stimulated with antiIgM and anti-IgG. Against IgG-containing immune complexdriven low affinity activating FcγRIIa and FcγRIII end points in peripheral blood mononuclear cells, BMS-935177 effectively inhibits TNFα production (IC50 = 14 nM). BMS-935177 shows mean IC50 values of 550 and 2060 nM in human and mouse whole blood, respectively[1]. |
| In vivo | BMS-935177(5, 20, and 45 mg/kg) inhibits anti-KLH antibodies of the IgG isotype at day 14, with statistically significant reductions at all doses. In satellite mice, BMS-935177 (5 mg/kg) maintains the plasma concentration above the mouse whole blood BCR-stimulated CD69 IC50 value of 2 μM for only 5 h. BMS-935177(10, 20, and 30 mg/kg) provides dose-dependently reduces both the severity and incidence of clinically evident disease in this rodent model of RA. BMS-935177(10 mg/kg) reduces the disease severity about 40%, and the percentage of animals showing any signs of disease is reduced by a third[1]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.57 mM), Sonication is recommended. DMSO : 117 mg/mL (232.81 mM), Sonication is recommended. |
| Keywords | BTK | BMS-935177 | BMS935177 | BMS 935177 |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | CP-547632 | CHMFL-EGFR-202 | Sunvozertinib | Ibrutinib | IBT6A | Orelabrutinib | Remibrutinib | Atuzabrutinib | Tyrosinase-IN-16 | Birelentinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $259.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-10 | |
| $2180.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-10 | ||
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY